Skip to content
Sign in

RYTM · NASDAQ

Rhythm Pharmaceuticals (RYTM) Stock Price & Fundamentals

$565.07+0.31%+$1.74End-of-day price as of Oct 9, 2026

Rhythm Pharmaceuticals (RYTM) closed at $565.07 on Oct 9, 2026, up 0.31% from the previous close of $563.33.

Share price, past year

1Y +12.77%

52-week range $482.49 – $565.07. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$565.07
Sep 30, 2026$545.23
Aug 31, 2026$512.87
Jul 31, 2026$500.94
Jun 30, 2026$503.36
May 29, 2026$507.72
Apr 30, 2026$519.73
Mar 31, 2026$512.08
Feb 27, 2026$506.68
Jan 30, 2026$490.16
Dec 31, 2025$511.99
Nov 28, 2025$510.57
Oct 31, 2025$499.03

Key statistics

Market cap
$38.89B
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
$239.92M
Net income (TTM)
−$205.35M
Shares outstanding
68.8M
Dividend yield
—
52-week range
$482.49 – $565.07

Rhythm Pharmaceuticals's market cap is $38.89B, based on a share price of $565.07 and 68.8M shares outstanding as of Jun 30, 2026.

Financials

Rhythm Pharmaceuticals reported revenue of $189.76M for fiscal 2025, up 45.83% from fiscal 2024.

Rhythm Pharmaceuticals reported a net loss of $196.54M in fiscal 2025.

Fiscal 2025 revenue was the highest in the 10 years shown.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Rhythm Pharmaceuticals annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$189.76M+45.8%−$196.54M−103.6%−$3.11−$116.63M
FY2024ended Dec 31, 2024$130.13M+68.1%−$260.60M−200.3%−$4.34−$113.88M
FY2023ended Dec 31, 2023$77.43M+227.6%−$184.68M−238.5%−$3.20−$136.20M
FY2022ended Dec 31, 2022$23.64M+649.5%−$181.12M−766.2%−$3.47−$173.71M
FY2021ended Dec 31, 2021$3.15M—−$69.61M−2,207.1%−$1.40−$146.44M
FY2020ended Dec 31, 2020$0.00—−$134.00M—−$3.04−$122.19M
FY2019ended Dec 31, 2019$0.00—−$140.73M—−$3.86−$126.14M
FY2018ended Dec 31, 2018$0.00—−$74.06M——−$62.78M
FY2017ended Dec 31, 2017$0.00—−$33.71M——−$29.59M
FY2016ended Dec 31, 2016$0.00————−$24.28M
Rhythm Pharmaceuticals quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$71.26M−$49.30M−$0.73
Q1 FY2026ended Mar 31, 2026$60.11M−$55.64M−$0.83
Q4 FY2025ended Dec 31, 2025$57.25M−$47.51M—
Q3 FY2025ended Sep 30, 2025$51.30M−$52.90M−$0.82
Q2 FY2025ended Jun 30, 2025$48.50M−$46.63M−$0.75
Q1 FY2025ended Mar 31, 2025$32.70M−$49.50M−$0.81
Q4 FY2024ended Dec 31, 2024$41.83M−$43.33M—
Q3 FY2024ended Sep 30, 2024$33.25M−$43.64M−$0.73

Company profile

Name
Rhythm Pharmaceuticals, Inc.
Ticker
RYTM
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
222 Berkeley Street, 12th Floor, Boston, MA 02116
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001649904

Recent SEC filings

Frequently asked questions

What is Rhythm Pharmaceuticals's stock price?

Rhythm Pharmaceuticals (RYTM) closed at $565.07 on Oct 9, 2026, up 0.31% from the previous close of $563.33.

What is Rhythm Pharmaceuticals's market cap?

Rhythm Pharmaceuticals's market cap is $38.89B, based on a share price of $565.07 and 68.8M shares outstanding as of Jun 30, 2026.

How much revenue does Rhythm Pharmaceuticals make?

Rhythm Pharmaceuticals reported revenue of $189.76M for fiscal 2025, up 45.83% from fiscal 2024.

Does Rhythm Pharmaceuticals pay a dividend?

Rhythm Pharmaceuticals's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Rhythm Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures